NEW YORK (GenomeWeb News) — BioWisdom will again use its KnowledgeScan software to help Pfizer in a drug-discovery project, BioWisdom said yesterday.
Pfizer plans to use the software to “assess the market opportunity, potential strategy, and clinical trial design” for an undisclosed class of compounds, BioWisdom said.
Financial terms of the agreement were not released.
A similar agreement was penned in June 2006.